Pfizer's Earnings Beat Dampened by Prevnar Shortfall

The transcript discusses Pfizer's recent sales performance, highlighting a downturn in Prevnar sales attributed to pent-up demand. Despite this, Pfizer's new products, Ibrance and Xeljanz, are performing well. The potential split of Pfizer into two companies is a major topic, with investors seeking clarity. Pfizer maintains its guidance for the year, with expectations for its new drugs to become major blockbusters.

What are the reasons attributed to the downturn in Prevnar sales?

How are analysts reacting to Pfizer's sales performance?

What are the two new products that Pfizer is counting on for future success?

What is the current status of the split-up of Pfizer's two companies?

What major question are investors asking regarding Pfizer's future?